ArticleCureus2026
Utility of the Inflammatory Bowel Disease Serology, Genetics, and Inflammation (IBD-SGI) Panel in the Evaluation of Atypical Ulcerative Colitis With Active Nonsteroidal Anti-Inflammatory Drug Use: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematochezia has a broad differential, including nonsteroidal anti-inflammatory drug (NSAID)-induced, infectious, and inflammatory colitis. Colonoscopy with biopsy is primarily used to evaluate suspected colitis or inflammatory bowel disease (IBD) in patients with hematochezia, rather than to diagnose all causes of hematochezia. While the inflammatory bowel disease serology, genetics, and inflammation (IBD-SGI) blood panel test has been studied and marketed by laboratories, it is not widely implemented in routine clinical practice due to the restriction of current clinical guidelines, lack of FDA clearance/approval, and limited medical insurance coverage. Thus, we report a case of the utility of the IBD-SGI panel in the evaluation of atypical ulcerative colitis (UC) with active NSAID use. A 39-year-old man with hematochezia, diarrhea, and chronic high-dose NSAID use developed anemia, elevated fecal calprotectin, and endoscopic evidence of inflammation. Biopsies by colonoscopy showed focal colitis with features suggestive of both NSAID injury and IBD. To provide additional diagnostic support in this challenging case, an IBD-SGI blood panel was used. When interpreted with the patient's clinical presentation, elevated fecal calprotectin level, colonoscopic findings, and histopathologic features, the panel results supported a diagnosis of UC. Based on the overall clinic-pathological assessment, including continuous circumferential inflammation on colonoscopy and histopathologic evidence of chronic IBD, the patient was diagnosed with UC and treatment with vedolizumab was initiated. Anemia attributed to hematochezia was also managed. At the three-month follow-up, the patient had resumed his daily activities and returned to work. In the setting of overlapping features of UC and possible NSAID-associated colitis, the IBD-SGI panel provided adjunctive diagnostic information. This case highlights the panel's potential value as a supportive tool when endoscopic biopsy findings are inconclusive and multiple possible etiologies coexist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.